Noxilizer has created the latest advancement in sterilization for the pharma, biotech and medical device industries. The recently launched UltraNox NO2 Production Sterilizer offers important benefits and addresses the shortcoming of ethylene oxide sterilization. Our proprietary nitrogen dioxide sterilization approach allows products to be sterilized at ultra low temperature to maintain product integrity especially in temperature sensitive biologicals, has a shorter degassing time which simplifies logistics, and this is a surface sterilant which does not impact product effectiveness and shelf life. Lastly, this process is non-carcinogenic versus the leading sterilization process ethylene oxide. Exciting times at Noxilizer as we are in product validation and heading toward FDA and EMA approval with many of our customers novel products lines.

Micro Interventional Devices is developing disruptive technologies that are revolutionizing percutaneous and minimally invasive structural heart repair procedures. Our proprietary technology is based on a breakthrough in soft- tissue anchoring and associated delivery devices that enable off-pump procedures.

Sinaptica Therapeutics has developed a non invasive personalized closed loop neuromodulation therapy that has shown in a clinical study to slow the progression of Alzheimer Disease by using EEG to target and to determine the neurostimulation dose delivered to the neuronal network involved in brain memory.

Advising and consulting with Private Equity, Venture Firms and CEOs.

Category creator, the first office and outpatient medical device for the treatment of depressionTurn around, from -3% growth to 25% CAGR for six years, $23M to $62MSuccessful new capital Venture rounds, $40M and a cross over round of $20, all up roundsTop performing IPO in Med Device, $93.5M, 14x oversubscribed, peek Mkt Cap $750m, 17x TTM RevenueReimbursement coverage expansion from 40% to 99%Rapid scaling in both operations and commercial organization, 90 to 265 employeesInternational regulatory and reimbursement approvals, JapanLabel expansion and clinical trial success

Reichert Technologies, now part of AMETEK, Inc., is a global leader in the design and manufacture of high quality diagnostic instruments and equipment for ophthalmologists, optometrists, opticians and retail eye centers, for the last 175 years. Reichert enjoys an excellent reputation within the eye care industry working with eye care practitioners around the world with over 70 products to diagnose eye disease, enhance vision and improve patients’ quality of life.Top line expansion through Private Label partnerships, BRIC's expansion and attaining a Category 1 code and reimbursement for our flagship product.Improved cash flow by reducing inventory, improving manufacturing turn rates, and decreasing warranty expenses by improving quality.Expanded gross margin by moving low margin high volumes to a low cost country.Top line growth restored by reposition existing products, both messaging and pricing. Ensured longer term growth by realigning our product development pipeline based on customer needs, competitive forces and organizational capabilities. http://www.reichert.com/index.cfm

-Responsible for improving the economies of the Neurosurgery division short and long term and the efficiency of the functions (Sales, Marketing, Finance, Product Development, Regulatory, Quality, Human Resources, Legal, Clinical and Scientific Affairs) that comprise the division.-We strive to address Neurosurgeons unmet clinical and service needs better than anyone else in Neurosurgery.-Integra Neurosurgery, "We limit uncertainty for the busiest Neurosurgeons"